# Alopecia Areata: Immunopathogenesis and JAK Inhibitors

## Introduction

Alopecia areata (AA) is an autoimmune, non-scarring alopecia characterized by the loss of immune privilege of the hair follicle and subsequent T-cell-mediated attack on anagen hair bulbs. Affecting approximately 2% of the global population over a lifetime, it ranges from isolated patches to total body hair loss. The advent of JAK inhibitors has revolutionized treatment, offering the first FDA-approved systemic therapy for severe AA.

## Epidemiology

The lifetime prevalence of alopecia areata is approximately 2%, with no significant sex predilection. The majority of patients present before age 40, and 60% present before age 20. AA is associated with other autoimmune conditions, including **thyroid disease** (8 to 28%), **vitiligo** (4%), **type 1 diabetes**, **pernicious anemia**, and **celiac disease**. An **atopic diathesis** (atopic dermatitis, asthma, allergic rhinitis) is present in 40 to 50% of AA patients and is associated with more severe disease. Family history is positive in 10 to 20% of cases, and the concordance rate in monozygotic twins is 55%.

## Immunopathogenesis

### Hair Follicle Immune Privilege

The anagen hair bulb is an **immune-privileged site** characterized by minimal MHC class I expression, local production of immunosuppressive factors (TGF-beta, alpha-MSH, IDO), and the absence of antigen-presenting cells. In AA, this immune privilege **collapses**: MHC class I and II are upregulated on follicular epithelial cells, exposing previously hidden autoantigens to the immune system. Triggers for this collapse may include viral infections, emotional stress, vaccination, or stochastic events.

### The NKG2D-MICA/ULBP Axis

Stressed follicular cells express **NKG2D ligands** (MICA, ULBP3) that activate **NKG2D+ CD8+ T cells** and NK cells. This represents a key early event in the breakdown of immune privilege.

### The IFN-gamma-JAK-STAT Axis

**CD8+ NKG2D+ T cells** produce **IFN-gamma**, which acts on follicular epithelial cells through the **JAK1/JAK2-STAT1** signaling pathway. IFN-gamma further upregulates MHC class I and II expression and induces chemokines CXCL9, CXCL10, and CXCL11 (CXCR3 ligands), creating a positive feedback loop that recruits more CD8+ T cells to the follicle. This produces a characteristic **"swarm" of peribulbar CD8+ T cells**, the classic histopathologic finding described as a **"swarm of bees"** pattern. **IL-15** produced by follicular cells through **JAK1/JAK3-STAT5** signaling further amplifies CD8+ T cell survival and cytotoxicity. The centrality of the JAK-STAT pathway to this entire process explains the remarkable efficacy of JAK inhibitors in treating AA.

### Genetic Susceptibility

**HLA-DRB1*11:04** is the strongest genetic risk factor. Genome-wide association studies have identified more than 14 risk loci, including genes involved in T-cell activation (CTLA4, IL2/IL2RA), innate immunity (ULBP3/ULBP6), and hair follicle biology (PRDX5, STX17).

<image>Diagram of the immunopathogenesis of alopecia areata showing: collapse of hair follicle immune privilege, NKG2D-MICA interaction, IFN-gamma production by CD8+ T cells, JAK1/JAK2-STAT1 signaling cascade in follicular cells, and the positive feedback loop through CXCL9/10/11 chemokine recruitment, with labeled sites of JAK inhibitor blockade</image>

## Clinical Presentation

### Patterns of Hair Loss

**Patchy AA** is the most common presentation, consisting of one or more well-circumscribed, smooth, round or oval patches of hair loss. **Alopecia totalis (AT)** involves complete loss of scalp hair. **Alopecia universalis (AU)** involves complete loss of all body hair, including eyebrows, eyelashes, and body hair. The **ophiasis pattern** describes band-like hair loss along the temporal and occipital margins and is associated with poorer prognosis. **Sisaipho (ophiasis inversus)** is the reverse pattern, with band-like loss along the frontoparietal scalp and preservation of the peripheral hairline. **Diffuse AA (alopecia incognita)** presents as acute, diffuse thinning that mimics telogen effluvium and is more common in young women.

### Clinical Signs

**Exclamation point hairs** are short (3 to 4 mm), dystrophic hairs that taper proximally and are found at the margins of active patches. **Cadaverized hairs (black dots)** are broken hairs at the scalp surface representing fractured dystrophic anagen hairs. **Yellow dots** on trichoscopy represent hyperkeratotic plugs in empty follicular ostia and are the most sensitive trichoscopic marker. **Nail changes** include fine pitting (geometric "grid-like" pitting), trachyonychia (rough, sandpaper-like nails), and red lunulae, present in 10 to 20% of patients.

### Prognostic Factors

Poor prognostic indicators include early onset (prepubertal), ophiasis pattern, AT/AU, long duration (over 1 year), nail involvement, associated atopy, positive family history, and concomitant autoimmune disease. Better prognosis is associated with adult onset, limited patches (fewer than 5), short duration, and no nail involvement.

## Diagnosis

The diagnosis is primarily clinical, based on the characteristic pattern, exclamation point hairs, and preserved follicular ostia. **Trichoscopy** reveals yellow dots, black dots, exclamation point hairs, short vellus hairs, broken hairs, and coudability hairs. **Scalp biopsy** shows a peribulbar lymphocytic infiltrate around anagen or early catagen follicles ("swarm of bees"), miniaturized follicles in chronic disease, and a catagen/telogen shift. Laboratory screening should include TSH and CBC, with consideration of ANA, vitamin D, and ferritin.

## Treatment

### Topical and Intralesional Therapies (Limited/Patchy Disease)

**Intralesional triamcinolone acetonide (ILT)** at 2.5 to 10 mg/mL is first-line for limited patchy AA. It is injected into the mid-dermis every 4 to 6 weeks and is effective in 60 to 70% of patients with limited disease. **Potent topical corticosteroids** (clobetasol) are an alternative for patients who decline injections or for children. **Topical minoxidil 5%** is an adjunctive therapy that promotes regrowth but does not address the underlying inflammation. **Topical immunotherapy** with diphenylcyclopropenone (DPCP) or squaric acid dibutylester (SADBE) induces allergic contact dermatitis to redirect the immune response and achieves a 50 to 60% response rate in extensive AA. **Topical JAK inhibitors** (ruxolitinib, tofacitinib) are under investigation, but limited penetration to the follicular bulb reduces their efficacy compared to systemic therapy.

### Systemic JAK Inhibitors (Moderate-Severe AA)

#### Baricitinib

Baricitinib is a **JAK1/JAK2 inhibitor** and was the first FDA-approved treatment for severe AA in adults (June 2022). The **BRAVE-AA1 and BRAVE-AA2 trials** demonstrated that 4 mg daily achieved a SALT score of 20 or less (near-complete regrowth) in approximately 39% of patients at 36 weeks versus 6% with placebo. Continued improvement occurred through week 52, though relapse is common upon discontinuation.

#### Ritlecitinib

Ritlecitinib is a **JAK3/TEC family kinase inhibitor** FDA-approved for severe AA in patients aged 12 and older (June 2023). The **ALLEGRO-2b/3 trial** showed that 50 mg daily achieved a SALT score of 20 or less in 23% of patients at 24 weeks. It may have a more targeted mechanism by inhibiting JAK3 (critical for IL-15 signaling) and TEC kinases in T and NK cells.

#### Deuruxolitinib

Deuruxolitinib is a **JAK1/JAK2 inhibitor** FDA-approved for adults with severe AA. The **THRIVE-AA1 trial** showed that 8 mg twice daily achieved a SALT score of 20 or less in approximately 32% at 24 weeks. It demonstrates strong efficacy for eyebrow and eyelash regrowth.

| JAK Inhibitor | Target | Dose | SALT ≤20 Response | FDA Approval |
|--------------|--------|------|-------------------|-------------|
| Baricitinib | JAK1/JAK2 | 4 mg daily | ~39% at 36 weeks | Adults, severe AA (2022) |
| Ritlecitinib | JAK3/TEC kinases | 50 mg daily | ~23% at 24 weeks | Age ≥12, severe AA (2023) |
| Deuruxolitinib | JAK1/JAK2 | 8 mg BID | ~32% at 24 weeks | Adults, severe AA |

#### Safety Considerations for JAK Inhibitors

Important safety considerations include infections (particularly herpes zoster reactivation, for which pre-treatment vaccination should be considered), upper respiratory infections, and laboratory abnormalities including lymphopenia, neutropenia, elevated CPK, lipid elevations, and transaminase elevations. A boxed warning regarding cardiovascular and thromboembolic risk was extrapolated from rheumatoid arthritis studies (the ORAL Surveillance trial with tofacitinib), though this risk appears lower in the younger, healthier AA population. Malignancy risk is a theoretical concern, but long-term data in AA are reassuring. Pre-treatment screening should include CBC, hepatic panel, lipids, hepatitis B and C testing, tuberculosis screening, age-appropriate cancer screening, and a vaccination review with live vaccines administered before initiation.

<image>Bar graph comparing clinical trial efficacy results (percentage of patients achieving SALT score <=20 at 36 weeks) for baricitinib 4mg, ritlecitinib 50mg, and deuruxolitinib 8mg BID versus placebo in severe alopecia areata</image>

### Other Systemic Therapies

**Systemic corticosteroids** in pulse dosing (oral prednisolone monthly pulses or IV methylprednisolone) can arrest progression, but relapse is near-universal upon discontinuation, and significant long-term adverse effects limit their utility. **Methotrexate** has limited evidence but may be useful in combination with low-dose corticosteroids. **Cyclosporine** can induce regrowth, but relapse is common, and nephrotoxicity limits prolonged use.

### Supportive Measures

AA carries significant psychosocial burden, and patients should be screened for depression and anxiety with referral for counseling as appropriate. **Wigs and hairpieces** are important options, and insurance coverage advocacy and National Alopecia Areata Foundation resources should be shared. **Sun protection** for the exposed scalp includes sunscreen and UV-protective headwear. **Eyelash and eyebrow prosthetics** provide cosmetic options for AT/AU patients.

<image>Clinical before-and-after photographs showing hair regrowth response in a patient with alopecia totalis treated with baricitinib 4mg daily over 36 weeks, demonstrating progressive regrowth from baseline through weeks 12, 24, and 36</image>

## Key Clinical Pearls

The IFN-gamma-JAK-STAT signaling axis is the central pathogenic pathway in AA, and this understanding directly led to the development of JAK inhibitor therapy. JAK inhibitors are disease-suppressive, not curative, and relapse rates upon discontinuation are high, necessitating long-term treatment in most patients. Exclamation point hairs and yellow dots on trichoscopy are the most characteristic diagnostic findings. Ophiasis pattern and nail involvement indicate more refractory disease requiring earlier escalation to systemic therapy. All patients should be screened for thyroid disease and counseled about the autoimmune nature of the condition.

## References

1. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med*. 2014;20(9):1043-1049.
2. King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. *N Engl J Med*. 2022;386(18):1687-1699.
3. King B, Mesinkovska N, Engstrom A, et al. Ritlecitinib for the treatment of alopecia areata: results from the ALLEGRO phase 2b/3 randomized trial. *J Am Acad Dermatol*. 2023;89(5):911-921.
4. Gilhar A, Etzioni A, Paus R. Alopecia areata. *N Engl J Med*. 2012;366(16):1515-1525.